UNSPSC 51151640: Fenpiverinium

This classification denotes an antimuscarinic agent with the molecular formula C22H29N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KP2L8LC73B. European Medicines Agency schedules fenpiverinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02124MIG. FENPIVERINIUM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, FENPIVERINIUM remains the US FDA Preferred Term for this commodity.

Fenpiverinium bears US NLM identifiers UMLS ID C0060190 and NCI Concept Code C87638. SMILES: C[N+]1(CCCCC1)CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N.

UNSPSC 51151640 Fenpiverinium, a Commodity code, nominally addresses a specific pharmaceutical ingredient, but recent state and local solicitations under this code show minimal alignment with the code's abstract scope. The recent opportunities tagged to this code involve naloxone procurement and direct-to-manufacturer pharmacy prescription programs — neither of which centers on fenpiverinium as a standalone ingredient. State and local issuing bodies accessing this code appear to be health and human services agencies, including county health departments and state HHS commissions, procuring naloxone kits, drug deactivation systems, and pharmacy benefit management services rather than fenpiverinium specifically. The mismatch between the code's nominal definition and actual purchasing activity suggests either broad categorization practice within state and local procurement systems or data-tagging inconsistency.

The geographic activity documented is concentrated in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a bid response deadline of July 26, 2023. The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs and pharmacy benefit contracting arrangements, representing an exploratory phase prior to formal competitive solicitation. These opportunities reflect state and local demand for pharmaceutical products and pharmacy program services, though the code's utility as a procurement signal appears limited by its mismatch with actual buying patterns.